Janus Henderson Group’s CRISPR Therapeutics CRSP Stock Holding History

Janus Henderson Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.92M	Buy	40,274 +5,500	+16%	+$290K	﹤0.01%	1366
2025 Q4	$1.82M	Hold	34,774	–	–	﹤0.01%	1386
2025 Q3	$2.25M	Hold	34,774	–	–	﹤0.01%	1279
2025 Q2	$1.69M	Hold	34,774	–	–	﹤0.01%	1366
2025 Q1	$1.29M	Hold	34,774	–	–	﹤0.01%	1495
2024 Q4	$1.37M	Hold	34,774	–	–	﹤0.01%	1514
2024 Q3	$1.63M	Hold	34,774	–	–	﹤0.01%	1410
2024 Q2	$1.88M	Hold	34,774	–	–	﹤0.01%	1285
2024 Q1	$2.37M	Hold	34,774	–	–	﹤0.01%	1213
2023 Q4	$2.18M	Hold	34,774	–	–	﹤0.01%	1211
2023 Q3	$1.58M	Hold	34,774	–	–	﹤0.01%	1308
2023 Q2	$1.95M	Hold	34,774	–	–	﹤0.01%	1259
2023 Q1	$1.57M	Buy	34,774 +21,512	+162%	+$1.04M	﹤0.01%	1391
2022 Q4	$539K	Sell	13,262 -13,262	-50%	-$704K	﹤0.01%	1679
2022 Q3	$1.73M	Buy	26,524 +11,662	+78%	+$845K	﹤0.01%	1374
2022 Q2	$903K	Buy	14,862 +2,989	+25%	+$176K	﹤0.01%	1392
2022 Q1	$746K	Buy	+11,873	New	+$746K	﹤0.01%	1666

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group's CRSP Position: Q1 2026 in Review

Janus Henderson Group increased its CRISPR Therapeutics (CRSP) stake by 16% in Q1 2026, buying an estimated $290K and bringing the position to 40,274 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1366.

Janus Henderson Group first reported a position in CRSP in Q1 2022 and has held it in 17 quarters since. The position peaked at $2.37M in Q1 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Janus Henderson Group held 40,274 shares of CRISPR Therapeutics worth $1.92M as of Q1 2026.
Janus Henderson Group bought 5,500 CRISPR Therapeutics shares in Q1 2026, an estimated $290K.
CRISPR Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1366 holding.
Janus Henderson Group first reported a position in CRISPR Therapeutics in Q1 2022 and has held it in 17 quarters since.
Janus Henderson Group's CRISPR Therapeutics position peaked at $2.37M in Q1 2024.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.